Guardant Health, Inc. (NASDAQ: GH) had its price target lowered by analysts at Sanford C. Bernstein from $40.00 to $35.00. They now have an "outperform" rating on the stock.
Guardant Health Named to TIME’s List of the Best Inventions of 2024
Table22 Closes $11M Series A to Power Food and Beverage Merchants' E-Commerce Growth [Yahoo! Finance]
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024 [Yahoo! Finance]
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024